Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
Phase 1
Completed
- Conditions
- Hodgkin's DiseaseAcute Myelogenous Leukemia (AML)Chronic Lymphocytic Leukemia (CLL)Non-Hodgkin's Lymphoma (NHL)Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: Single FT1050 treated UCB unit
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT01527838
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธDana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program, Boston, Massachusetts, United States
๐บ๐ธOhio State Univeristy Comprehensive Cancer Center, Columbus, Ohio, United States
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.
Phase 1
Completed
- Conditions
- Hematologic MalignanciesAllogeneic Stem Cell Transplantation
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT00890500
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath